 | • レポートコード：TPM-B04454 • 出版社/出版日：Transparency Market Research / 2018年1月 • レポート形態：英文、PDF、201ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、ドライアイの世界市場について調べ、ドライアイの世界規模、市場動向、市場環境、製品別分析、流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・ドライアイの世界市場動向 ・ドライアイの世界市場環境 ・ドライアイの世界市場規模 ・ドライアイの世界市場規模：製品別 ・ドライアイの世界市場規模：流通経路別 ・ドライアイの世界市場：地域別市場規模・分析 ・ドライアイの北米市場規模・予測 ・ドライアイのアメリカ市場規模・予測 ・ドライアイの中南米市場規模・予測 ・ドライアイのヨーロッパ市場規模・予測 ・ドライアイのアジア市場規模・予測 ・ドライアイの日本市場規模・予測 ・ドライアイの中国市場規模・予測 ・ドライアイのインド市場規模・予測 ・ドライアイの中東市場規模・予測 ・ドライアイのアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Dry Eye Disease Market: Overview
Dry eye is an ocular disease caused due to insufficiency or lack of tears in eye. Tears made up of three layers viz. lipids, mucin and aqueous keep eye moist and lubricated. Lack of tears lead to redness, burning, sensing and pain in eye. Dry eye disease also known as Keratoconjuctivitis Sicca is a common phenomenon, which is estimated to have prevalence of 8% to 34% across the globe. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye disease. Dry eye is a multifactorial disease, most of the currently approved prescription and currently approved dry eye treatment products are targeted to relief the signs and symptoms of dry eye disease. The choice of treatment depends upon the type and severity of dry eye disease.
Global Dry Eye Disease Market: Scope of the Study
This report on the dry eye disease market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.
Market related factors such as technological developments, product innovation, expansion of healthcare infrastructure facilities around the world, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the dry eye disease market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, product development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.
Global Dry Eye Disease Market: Key Segments
On the basis of products, the dry eye disease market is categorized into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogue and others. The anti-inflammatory drugs segment is further classified into cyclosporine, corticosteroids and lifitegrast. While the others segment include oral omega supplements, oral tetracycline and eye inserts. On the basis of distribution channel, the dry eye disease market is categorized into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.
Global Dry Eye Disease Market: Regional Outlook
On the basis of geography, the dry eye disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America comprises the U.S. and Canada. Europe comprises Germany, France, U.K., Spain, Italy and Rest of Europe. Asia-Pacific comprises China, India, Japan, Australia & New Zealand and Rest of Asia Pacific. Latin America comprises Brazil, Mexico and Rest of Latin America. Middle East & Africa comprises of GCC Countries, South Africa and Rest of Middle East & Africa.
Global Dry Eye Disease Market: Competitive Outlook
The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the dry eye disease market. The report also profiles major players in the dry eye disease market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and FCI S.A.S.
The global dry eye disease market has been segmented as follows:
Global Dry Eye Disease Market, by Product
Artificial Tears
Anti-inflammatory Drugs
Cyclosporine
Corticosteroids
Lifitegrast
Punctal Plugs
Secretagogue
Others
Global Dry Eye Disease Market, by Distribution Channel
Hospital Pharmacies
Independent Pharmacies & Drug Stores
Online Pharmacies
Global Dry Eye Disease Market, by Geography
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
Japan
China
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of MEA
Table of Content
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Dye Eye Disease Market
4. Market Overview
4.1. Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. High prevalence and rise in incidence rates of dry eye disease and associated risk factors
4.3.1.2. Technical advancements and promising pipeline products
4.3.1.3. Novel dry eye diagnostic tools in offering
4.3.1.4. Growing number of eye care centers prompting surge in product utilization
4.3.2. Restraints
4.3.2.1. High cost of specialty dry eye products with Unclear Reimbursement Scenario
4.3.2.2. Alternative therapies in offering
4.3.3. Opportunities
4.3.3.1. Development of novel treatments
4.4. Global Dye Eye Disease Market Analysis and Forecasts, 2015–2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7.Global Prevalence of Dry Eye Disease
4.8.Pipeline Analysis : Dry Eye Disease Drugs
4.9.Autologous Serum Tears – Overview
4.10.Key Industry Trends
5. Global Dye Eye Disease Market Analysis and Forecasts, By Product
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market value Forecast By Product, 2015–2025
5.4.1. Artificial Tears
5.4.2. Anti-inflammatory
5.4.2.1. Cyclosporine
5.4.2.2. Corticosteroid
5.4.2.3. Lifitegrast
5.4.3. Punctal Plugs
5.4.4. Secretagogue
5.4.5. Others
5.5. Market Attractiveness By Product
6. Global Dye Eye Disease Market Analysis and Forecasts, By Distribution Channel
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market value Forecast By Distribution Channel, 2015–2025
6.4.1. Hospital Pharmacies
6.4.2. Independent Pharmacies & Drug Stores
6.4.3. Online Pharmacies
6.5. Market Attractiveness By Distribution Channel
7. Global Dye Eye Disease Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Market value Forecast By Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness By Region
7.4. Key Trends, By Region
8. North America Dye Eye Disease Market Analysis and Forecast
8.1. Key Findings
8.2. Market value Forecast By Product, 2015–2025
8.2.1. Artificial Tears
8.2.2. Anti-inflammatory
8.2.2.1. Cyclosporine
8.2.2.2. Corticosteroid
8.2.2.3. Lifitegrast
8.2.3. Punctal Plugs
8.2.4. Secretagogue
8.2.5. Others
8.3. Market value Forecast By Distribution Channel, 2015–2025
8.3.1. Hospital Pharmacies
8.3.2. Independent Pharmacies & Drug Stores
8.3.3. Online Pharmacies
8.4. Market value Forecast By Country, 2015–2025
8.4.1. US
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product
8.5.2. By Distribution Channel
8.5.3. By Country
9. Europe Dye Eye Disease Market Analysis and Forecast
9.1. Key Findings
9.2. Market value Forecast By Product, 2015–2025
9.2.1. Artificial Tears
9.2.2. Anti-inflammatory
9.2.2.1. Cyclosporine
9.2.2.2. Corticosteroid
9.2.2.3. Lifitegrast
9.2.3. Punctal Plugs
9.2.4. Secretagogue
9.2.5. Others
9.3. Market value Forecast By Distribution Channel, 2015–2025
9.3.1. Hospital Pharmacies
9.3.2. Independent Pharmacies & Drug Stores
9.3.3. Online Pharmacies
9.4. Market value Forecast By Country / Sub-region, 2015–2025
9.4.1. Germany
9.4.2. UK
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country / Sub-region
10. Asia Pacific Dye Eye Disease Market Analysis and Forecast
10.1.Key Findings
10.2.Market value Forecast By Product, 2015–2025
10.2.1. Artificial Tears
10.2.2. Anti-inflammatory
10.2.2.1. Cyclosporine
10.2.2.2. Corticosteroid
10.2.2.3. Lifitegrast
10.2.3. Punctal Plugs
10.2.4. Secretagogue
10.2.5. Others
10.3.Market value Forecast By Distribution Channel, 2015–2025
10.3.1. Hospital Pharmacies
10.3.2. Independent Pharmacies & Drug Stores
10.3.3. Online Pharmacies
10.4.Market value Forecast By Country / Sub-region, 2015–2025
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia and New Zealand
10.4.5. Rest of APAC
10.5.Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country / Sub-region
11. Latin America Dye Eye Disease Market Analysis and Forecast
11.1.Key Findings
11.2.Market value Forecast By Product, 2015–2025
11.2.1. Artificial Tears
11.2.2. Anti-inflammatory
11.2.2.1. Cyclosporine
11.2.2.2. Corticosteroid
11.2.2.3. Lifitegrast
11.2.3.Punctal Plugs
11.2.4. Secretagogue
11.2.5. Others
11.3.Market value Forecast By Distribution Channel, 2015–2025
11.3.1. Hospital Pharmacies
11.3.2. Independent Pharmacies & Drug Stores
11.3.3. Online Pharmacies
11.4.Market value Forecast By Country / Sub-region, 2015–2025
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of LATAM
11.5.Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country / Sub-region
12. Middle East & Africa Dye Eye Disease Market Analysis and Forecast
12.1.Key Findings
12.2.Market value Forecast By Product, 2015–2025
12.2.1. Artificial Tears
12.2.2. Anti-inflammatory
12.2.2.1. Cyclosporine
12.2.2.2. Corticosteroid
12.2.2.3. Lifitegrast
12.2.3. Punctal Plugs
12.2.4. Secretagogue
12.2.5. Others
12.3.Market value Forecast By Distribution Channel, 2015–2025
12.3.1. Hospital Pharmacies
12.3.2. Independent Pharmacies & Drug Stores
12.3.3. Online Pharmacies
12.4.Market value Forecast By Country / Sub-region, 2015–2025
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Israel
12.4.4. Rest of MEA
12.5.Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country / Sub-region
13. Competition Landscape
13.1.Market Player – Competition Matrix (By Tier and Size of companies)
13.2.Market Share Analysis By Company (2016)
13.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.3.1. Santen Pharmaceutical Co., Ltd.
13.3.1.1. Company Overview
13.3.1.2. Business Overview
13.3.1.3. Product Overview
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.1.6. SWOT Analysis
13.3.2. Novartis AG
13.3.2.1. Company Overview
13.3.2.2. Business Overview
13.3.2.3. Product Overview
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.2.6. SWOT Analysis
13.3.3. Valeant Pharmaceuticals International, Inc.
13.3.3.1. Company Overview
13.3.3.2. Business Overview
13.3.3.3. Product Overview
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.3.6. SWOT Analysis
13.3.4. Allergan plc
13.3.4.1. Company Overview
13.3.4.2. Business Overview
13.3.4.3. Product Overview
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.4.6. SWOT Analysis
13.3.5. Shire plc
13.3.5.1. Company Overview
13.3.5.2. Business Overview
13.3.5.3. Product Overview
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.5.6. SWOT Analysis
13.3.6. TRB Chemedica International SA
13.3.6.1. Company Overview
13.3.6.2. Business Overview
13.3.6.3. Product Overview
13.3.6.4. Strategic Overview
13.3.6.5. SWOT Analysis
13.3.7. Sun Pharmaceutical Industries Ltd.
13.3.7.1. Company Overview
13.3.7.2. Business Overview
13.3.7.3. Product Overview
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.7.6. SWOT Analysis
13.3.8. Senju Pharmaceutical Co., Ltd.
13.3.8.1. Company Overview
13.3.8.2. Business Overview
13.3.8.3. Product Overview
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview
13.3.8.6. SWOT Analysis
13.3.9. Sentiss Pharma Pvt. Ltd.
13.3.9.1. Company Overview
13.3.9.2. Business Overview
13.3.9.3. Product Overview
13.3.9.4. Strategic Overview
13.3.9.5. SWOT Analysis
13.3.10. Johnson & Johnson
13.3.10.1. Company Overview
13.3.10.2. Business Overview
13.3.10.3. Product Overview
13.3.10.4. Financial Overview
13.3.10.5. Strategic Overview
13.3.10.6. SWOT Analysis
13.3.11. Otsuka Pharmaceutical Co., Ltd.
13.3.11.1. Company Overview
13.3.11.2. Business Overview
13.3.11.3. Product Overview
13.3.11.4. Financial Overview
13.3.11.5. Strategic Overview
13.3.11.6. SWOT Analysis
13.3.12. Mitotech S.A.
13.3.12.1. Company Overview
13.3.12.2. Business Overview
13.3.12.3. Product Overview
13.3.12.4. Strategic Overview
13.3.12.5. SWOT Analysis
13.3.13. FCI S.A.S.
13.3.13.1. Company Overview
13.3.13.2. Business Overview
13.3.13.3. Product Overview
13.3.13.4. Strategic Overview
13.3.13.5. SWOT Analysis
Table 01: Pipeline Analysis (1/5)
Table 02: Pipeline Analysis (2/5)
Table 03: Pipeline Analysis (3/5)
Table 04: Pipeline Analysis (4/5)
Table 05: Pipeline Analysis (5/5)
Table 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 07: Global Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 08: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 09: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 11: North America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 12: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 13: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Europe Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 15: Europe Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 16: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 17: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 18: Asia Pacific Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 19: Asia Pacific Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 20: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 21: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 22: Latin America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 23: Latin America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 24: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 25: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 26: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 27: Middle East & Africa Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 28: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 29: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025